Published in Sci Rep on December 09, 2016
Osteoclast differentiation and activation. Nature (2003) 18.59
Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 5.76
Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med (2005) 3.42
A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med (2001) 3.18
Cutting edge: TREM-2 attenuates macrophage activation. J Immunol (2006) 3.07
Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol (2006) 2.73
TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med (2007) 2.62
TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol (2009) 2.44
Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol (2007) 2.08
DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med (2003) 2.04
Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol (2007) 1.88
Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med (2003) 1.80
p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology (2002) 1.52
TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res (2005) 1.48
The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur J Immunol (2003) 1.22
Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. Hum Immunol (2013) 1.16
Membrane-type matrix metalloproteinases: Their functions and regulations. Matrix Biol (2015) 1.08
TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB. Oncogene (2010) 1.06
The enigmatic function of TREM-2 in osteoclastogenesis. Adv Exp Med Biol (2007) 1.05
Congenital cholesteatoma: theories, facts, and 53 patients. Otolaryngol Clin North Am (2006) 1.00
Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK. J Cell Biochem (2011) 0.98
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. Gastroenterology (2012) 0.90
TREM-2 promotes host resistance against Pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway. Invest Ophthalmol Vis Sci (2013) 0.90
Experimental retraction pocket cholesteatoma. Ann Otol Rhinol Laryngol (1987) 0.89
Triggering receptor expressed on myeloid cells receptor family modulators: a patent review. Expert Opin Ther Pat (2014) 0.86
Toll-like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma. Eur Arch Otorhinolaryngol (2006) 0.86
Dual Effect of Cyanidin on RANKL-Induced Differentiation and Fusion of Osteoclasts. J Cell Physiol (2016) 0.85
TREM-2 promotes macrophage-mediated eradication of Pseudomonas aeruginosa via a PI3K/Akt pathway. Scand J Immunol (2014) 0.84
Cholesteatoma growth and proliferation: relevance with serpin B3. Laryngoscope (2012) 0.82
The effect of BMP-2, BMP-4 and BMP-6 on bone destruction of cholesteatoma presence. Am J Otolaryngol (2013) 0.81
Notes on the microbiology of cholesteatoma: clinical findings and treatment. Acta Otorhinolaryngol Ital (2009) 0.81
Silencing of triggering receptor expressed on myeloid cells-2 enhances the inflammatory responses of alveolar macrophages to lipopolysaccharide. Mol Med Rep (2013) 0.81
Keratin particle-induced osteolysis: a mouse model of inflammatory bone remodeling related to cholesteatoma. J Assoc Res Otolaryngol (2001) 0.81
Expression of RANKL and OPG in middle ear cholesteatoma tissue. Laryngoscope (2006) 0.81
A murine model of cholesteatoma-induced bone resorption using autologous dermal implantation. Laryngoscope (2003) 0.80
Modulation of bone resorption by phosphorylation state of bone sialoprotein. Biochemistry (2009) 0.80
Construction of a recombinant eukaryotic expression plasmid containing human calcitonin gene and its expression in NIH3T3 cells. J Biomed Biotechnol (2009) 0.79
Chronic otitis media with cholesteatoma: middle ear/inner ear interaction. Otol Neurotol (2009) 0.78
Animal models of middle ear cholesteatoma. J Biomed Biotechnol (2011) 0.78
Expression of pattern recognition receptors in cholesteatoma. Eur Arch Otorhinolaryngol (2013) 0.78
Cholesteatoma. BMJ (2011) 0.78
[Mechanism of osteoclast in bone resorption]. Zhongguo Gu Shang (2014) 0.77
Autologous meatal skin graft implantation and intratympanic injection of Pseudomonas aeruginosa: a new experimental mouse model of acquired middle ear cholesteatoma. ORL J Otorhinolaryngol Relat Spec (2013) 0.77
[Expression of osteoclast stimulating and differentiating factors in a murine model of localized inflammatory bone resorption]. Laryngorhinootologie (2004) 0.77
A review of current progress in acquired cholesteatoma management. Eur Arch Otorhinolaryngol (2014) 0.77
Management of acquired cholesteatoma in children: a 15 year review in ENT service of CHNU de FANN Dakar. Int J Pediatr Otorhinolaryngol (2013) 0.76
Expression of toll-like receptors in chronic otitis media and cholesteatoma. Int J Pediatr Otorhinolaryngol (2013) 0.76
[Bone destruction caused by osteoclasts]. Clin Calcium (2006) 0.76
Acquired cholesteatoma in children following congenital cholesteatoma surgery. Int J Pediatr Otorhinolaryngol (2010) 0.76
Management of cholesteatoma. Otolaryngol Clin North Am (1989) 0.76